MannKind Corp Announces $50M Private Placement; FDA Approves Furoscix

What Happened MannKind Corporation announced two material events: it completed a private placement that generated approximately $50.0 million in gross proceeds and disclosed that the U.S. Food and Drug Administration approved Furoscix ReadyFlow™ (furosemide injection) for treating edema in adults with heart failure or chronic kidney disease. The Securities Purchase Agreement was signed on July 23, 2026, and the closing occurred on July 24, 2026.

Key Details

• The Company sold 10,440,838 shares of common stock at $3.89 per share and issued pre-funded warrants underlying 2,412,632 shares at $3.88 per warrant share as part of the private placement.
• Total gross proceeds were approximately $50.0 million (before expenses). The Company intends to use net proceeds for general corporate purposes, including funding a $45.0 million contingent value rights (CVR) payment triggered by the FDA approval.
• Pre-funded warrants have an exercise price of $0.01 per share, do not expire until exercised in full, permit “cashless” net exercise, and include a beneficial ownership limitation (not to exceed 19.99%).
• The securities were sold in a private placement relying on Section 4(a)(2) of the Securities Act; MannKind agreed to file a registration statement for resale of the issued shares and warrant shares within 30 days of closing (subject to allowable delays).

Why It Matters For investors, the private placement strengthens MannKind’s cash position immediately (roughly $50M gross) and is being used in part to cover a near-term $45M CVR payment tied to the newly announced FDA approval. The FDA approval of Furoscix ReadyFlow is a regulatory milestone that may enable commercialization and related obligations, but the filing does not provide sales or revenue forecasts. The issuance of shares and pre-funded warrants dilutes existing shareholders; registration rights were granted so the new securities can be registered for resale.